<DOC>
	<DOCNO>NCT00371904</DOCNO>
	<brief_summary>About one third prospective kidney transplant recipient antibody blood direct tissue available kidney donor . Recently , `` desensitisation '' treatment administer pre-transplant allow successful transplantation patient despite high rate acute antibody mediate rejection ( AAMR ) . The investigator propose test randomise control trial whether rituximab , monoclonal antibody deplete B-lymphocytes , safely low antibody mediate rejection ( AMR ) rate add `` standard '' therapy . The investigator also test whether rituximab enables patient achieve negative crossmatch donor thereby allow transplant proceed .</brief_summary>
	<brief_title>Trial Rituximab Given Pre-Transplant Sensitised Live Donor Kidney Recipients</brief_title>
	<detailed_description>This study design investigate prospective , randomise fashion whether single intravenous dose rituximab ( 375 mg/m2 ) give two week prior transplant , addition standard therapy , allow sensitise renal transplant subject achieve negative CDC crossmatch thereby proceed live donor transplantation . We also evaluate whether rituximab reduce number AAMR episodes post-transplant period , compare control . All eligible subject must positive T- and/or B-cell CDC flow cytometry crossmatch donor-specific antibody identify solid-phase assay screening . All subject receive standard desensitisation regimen include plasma exchange/IVIG + MMF immediately transplantation follow standard care immunosuppressive regimen ( IL-2R antagonist , tacrolimus , mycophenolate mofetil [ MMF ] corticosteroid ) transplantation .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion criterion : 1 . Subjects , age &gt; 18 year 2 . Subjects receive single organ renal transplant live donor 3 . Positive Tcell and/or Bcell crossmatch complement dependent cytotoxicity ( CDC ) and/or positive flow cytometry crossmatch confirm donorspecific antibody solidphase assay screening . Positive CDC Tcell and/or Bcell crossmatch titre must less equal 1:64 . 4 . Subjects capable understanding purpose risk study give write informed consent Exclusion Criteria Study Entry ( 4 week prior transplant ) : 1 . Primary renal transplant lose acute rejection less six month prior randomisation 2 . Women childbearing potential positive serum urine pregnancy test nursing mother 3 . Subjects history malignancy ( non melanoma skin cancer totally excised recurrence two year ) 4 . Subjects know contraindication treatment rituximab 5 . Subjects haemoglobin &lt; 8.5 g/dL , WBC value &lt; 3000/mm3 platelet count &lt; 50,000/mm3 unlikely resolve prior randomisation 6 . Subjects positive ABO crossmatch donor 7 . Subjects severe diarrhoea gastrointestinal disorder might interfere ability absorb oral medication unlikely resolve prior randomisation 8 . Subjects participate another interventional clinical trial require treatment unmarketed investigational drug would expect require medication prohibit protocol 9 . Subjects follow study duration 10 . Subjects disorder condition may interfere ability comply study procedure and/or requirement Additional Exclusion Criteria Day 2 Transplantation : 1 . All exclusion criterion study entry 2 . Positive T and/or Bcell CDC crossmatch Day 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>donor</keyword>
	<keyword>sensitise</keyword>
	<keyword>antibody</keyword>
	<keyword>rejection</keyword>
</DOC>